Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29643703 | 1.00 | ENPP2 (0.41) | ENPP2ALDH1A1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL2404902 | 0.86 | KMT2A (0.36) | ENPP2ALDH1A1KMT2ALMNATSHR | |
| SCHEMBL246398 | 0.84 | ENPP2 (0.42) | ENPP2ALDH1A1KMT2ALMNATSHR | |
| SCHEMBL31208432 | 0.84 | ENPP2 (0.42) | ENPP2ALDH1A1KMT2ALMNATSHR | |
| SCHEMBL39406 | 0.76 | CES2 (0.43) | ALDH1A1KMT2ATDP1 | |
| SCHEMBL29375771 | 0.76 | TSHR (0.48) | ENPP2ALDH1A1KMT2ASLC6A2LMNA | |
| SCHEMBL12384874 | 0.76 | ESR2 (0.36) | LMNAHSD17B10ERN1 | |
| SCHEMBL29395656 | 0.76 | CES2 (0.43) | ALDH1A1KMT2ATDP1 | |
| SCHEMBL41990 | 0.76 | TSHR (0.48) | ENPP2ALDH1A1KMT2ASLC6A2LMNA | |
| SCHEMBL31414880 | 0.76 | ERN1 (0.36) | ENPP2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| WO-2024016826-A1 | 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF | 杭州市第七人民医院 | 2024-01-25 | — | — | WO | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| CN-115232090-A | 6-substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2,2-dioxide compound and preparation and application thereof | 杭州市第七人民医院 | 2022-10-25 | — | — | CN | claimed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | claimed |
| EP-2736912-B1 | METHODS OF ISOLATING 4-CHLORO-2-FLUORO-3-SUBSTITUTED-PHENYLBORONIC ACIDS | DOW AGROSCIENCES LLC (US) | 2018-06-13 | — | — | EP | claimed |
| EP-2797933-B1 | METHODS OF FORMING 4-CHLORO-2-FLUORO-3-SUBSTITUTED-PHENYLBORONIC ACID PINACOL ESTERS AND METHODS OF USING THE SAME | DOW AGROSCIENCES LLC (US) | 2017-08-16 | — | — | EP | claimed |
| US-20120065404-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | ACTAVIS GROUP PTC HF (IS) | 2012-03-15 | — | — | US | claimed |
| US-8101769-B2 | Chemical intermediate; high purity drug | ACTAVIS GROUP PTC EHF (IE) | 2012-01-24 | — | — | US | claimed |
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | ACTAVIS GROUP PTC EHF (IS) | 2010-08-05 | — | — | US | claimed |
| EP-2155706-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | Actavis Group PTC EHF (IS) | 2010-02-24 | — | — | EP | claimed |
| EP-2121644-A2 | IMPROVED PROCESS FOR PREPARING ETHYL (S)-2-ETHOXY-4-[N-[1-(2- PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYL METHYL]BENZOATE AND USE THEREOF FOR THE PREPARATION OF REPAGLINIDE | Actavis Group PTC EHF (IS) | 2009-11-25 | — | — | EP | claimed |
| WO-2009004485-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2009-01-08 | — | — | WO | claimed |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | ACTAVIS GROUP PTC HF (IS) | 2008-08-21 | — | — | US | claimed |
| WO-2008099286-A2 | IMPROVED PROCESS FOR PREPARING ETHYL (S)-2-ETHOXY-4-[N-[1-(2- PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYL METHYL]BENZOATE AND USE THEREOF FOR THE PREPARATION OF REPAGLINIDE | ACTAVIS GROUP PTC EHF (US) | 2008-08-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | EMG1, DAP3, DRD4 | ENPP2 3348/4885ALDH1A1 1800/4885KMT2A 2316/4885 |
| US-20120065404-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | MEP1B, GABRE, BPGM | ENPP2 2365/4885ALDH1A1 1646/4885KMT2A 958/4885 |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | MEP1B, GABRE, BPGM | ENPP2 2365/4885ALDH1A1 1646/4885KMT2A 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.